Elevated myelocytomatosis oncogene (MYC) expression is common in SCLC, has been associated with resistance to platinum chemotherapies, and is likely involved in immunotherapy response given evidence that it is involved in IFN signaling[79]. The gene discussed is MYC; the disease is small cell lung carcinoma.